Oral Solid Dosage Contract Manufacturing Market – By Product (Tablet, Capsule, Powder), Type (Immediate, Delayed, & Controlled Release), Therapeutic area (Oncology, Cardiovascular, Infectious, Metabolic), Service, End-use, Global Forecast (2024 – 2032)

Oral Solid Dosage Contract Manufacturing Market – By Product (Tablet, Capsule, Powder), Type (Immediate, Delayed, & Controlled Release), Therapeutic area (Oncology, Cardiovascular, Infectious, Metabolic), Service, End-use, Global Forecast (2024 – 2032)

Oral solid dosage contract manufacturing market size is expected to record 5.6% CAGR between 2024 and 2032. Lately, pharmaceutical companies are increasingly outsourcing the production of oral solid dosage forms, such as tablets, capsules, and powders to contract manufacturing organizations (CMOs) to reduce costs, improve production efficiency, and focus on core competencies like R&D activities. This is particularly prominent among small to mid-sized pharmaceutical firms looking to scale operations without investing in extensive manufacturing facilities.

The demand for generic drugs will also influence the market growth. As patents for branded drugs expire, there is a surge in the production of generic versions to meet the healthcare demands worldwide. Oral solid dosage forms are among the most prescribed medications as they offer expertise in formulation development, regulatory compliance, and manufacturing scale-up. Rising advancements in technology and quality standards to ensure consistent product quality and adherence to stringent regulatory requirements are also stimulating the market growth. For instance, in April 2024, Lupin unveiled Mirabegron extended-release tablets (25 mg) in the U.S. after approval from FDA.

The overall industry is segmented into product, type, therapeutic area, service, end-use, and region.

Based on product, the oral solid dosage contract manufacturing market from the capsules segment is expected to witness substantial growth rate through 2032 due to its increasing popularity as a preferred dosage form for both pharmaceutical companies and consumers. Capsules offer numerous advantages, including ease of swallowing, better bioavailability, and the ability to encapsulate a wide range of drug formulations, including powders, granules, and liquids. This versatility makes them ideal for a variety of therapeutic applications.

In terms of service, the oral solid dosage contract manufacturing industry from the API manufacturing segment is slated to generate notable revenue during 2024-2032. This is due to the critical role played by APIs (active pharmaceutical ingredients) in drug efficacy and formulation. As pharmaceutical companies strive to develop more effective and targeted therapies, there is an increasing demand for high-quality APIs that meet stringent regulatory standards.

Asia Pacific oral solid dosage contract manufacturing market will generate lucrative growth during 2024-2032. This is attributed to the substantial cost advantages offered by manufacturers in India and China, which provide high-quality production at lower costs compared to Western countries. The rapid expansion of the pharmaceutical industry, supported by increasing investments in healthcare infrastructure and R&D activities, is also fueling the demand for contract manufacturing services. The large and growing population, coupled with rising healthcare expenditure and the prevalence of chronic diseases, is further increasing the need for affordable and accessible medications, driving the regional industry expansion.